PET/CT imaging of GRPR in various cancers
Part of Cancer clinical trials.
This study tests a new PET/CT imaging agent that targets a protein called GRPR, which is found on many cancer cells. The goal is to see if this scan can help detect or evaluate various cancers, which might improve diagnosis and treatment planning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can give your informed consent.
- You have a cancer type that likely has GRPR on its cells (including certain breast, head and neck, lung, ovarian, prostate, or pancreatic cancers).
- You are generally able to manage daily activities (ECOG 0-3) and are under a doctor's care.
- You can lie still on your back with your arms up for up to 30 minutes during the scan.
- You are not pregnant or breastfeeding, and you do not have a known allergy to the imaging agent.
- You weigh less than 200 kg (440 lbs) and are able to fit inside the scanner.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging method (GRPR PET) to help better see and stage prostate cancer. If you have prostate cancer, this scan may give doctors more detail about where the cancer is located.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This trial tests an experimental PET imaging drug, called 68Ga-GP-01, to see if it can help show tumors and any spread of the cancer. The study will give you the imaging drug, then take a PET/CT scan. You may join if you have a solid tumor and are scheduled for surgery or a laparoscopic exploration to confirm the cancer.
This study tests a new type of imaging scan (PET/CT or PET/MR) that uses a radioactive tracer to help doctors better detect and diagnose various cancers. The scan targets a specific protein found in tumors, which may help identify cancer more accurately than standard imaging.
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
Hear when a new Malignancies Multiple trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.